Legal & General Group’s Soleno Therapeutics SLNO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-35,144
| Closed | -$1.18M | – | 3518 |
|
|
2026
Q1 | $1.18M | Sell |
35,144
-6,644
| -16% | -$260K | ﹤0.01% | 2092 |
|
|
2025
Q4 | $1.93M | Buy |
41,788
+1,847
| +5% | +$101K | ﹤0.01% | 1978 |
|
|
2025
Q3 | $2.7M | Buy |
39,941
+4,536
| +13% | +$336K | ﹤0.01% | 1859 |
|
|
2025
Q2 | $2.97M | Buy |
35,405
+9,073
| +34% | +$679K | ﹤0.01% | 1802 |
|
|
2025
Q1 | $1.88M | Buy |
26,332
+2,861
| +12% | +$139K | ﹤0.01% | 1948 |
|
|
2024
Q4 | $1.06M | Buy |
23,471
+3,416
| +17% | +$177K | ﹤0.01% | 2220 |
|
|
2024
Q3 | $1.01M | Buy |
20,055
+4,036
| +25% | +$193K | ﹤0.01% | 2231 |
|
|
2024
Q2 | $654K | Buy |
16,019
+3,736
| +30% | +$158K | ﹤0.01% | 2332 |
|
|
2024
Q1 | $526K | Buy |
12,283
+4,556
| +59% | +$206K | ﹤0.01% | 2403 |
|
|
2023
Q4 | $311K | Buy |
+7,727
| New | +$220K | ﹤0.01% | 2616 |
|
|
2021
Q2 | – | Sell |
-445
| Closed | -$8K | – | 3633 |
|
|
2021
Q1 | $8K | Hold |
445
| – | – | ﹤0.01% | 3436 |
|
|
2020
Q4 | $13K | Hold |
445
| – | – | ﹤0.01% | 3253 |
|
|
2020
Q3 | $17K | Buy |
445
+93
| +26% | +$2.72K | ﹤0.01% | 3029 |
|
|
2020
Q2 | $12K | Buy |
+352
| New | +$15.3K | ﹤0.01% | 3269 |
|
Legal & General Group's SLNO Position: Q2 2026 in Review
Legal & General Group sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 35,144 shares — an estimated $1.18M sold.
Legal & General Group first reported a position in SLNO in Q2 2020 and held it in 14 quarters. The position peaked at $2.97M in Q2 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.
- Legal & General Group reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
- Legal & General Group sold 35,144 Soleno Therapeutics shares in Q2 2026, an estimated $1.18M.
- Legal & General Group first reported a position in Soleno Therapeutics in Q2 2020 and held it in 14 quarters.
- Legal & General Group's Soleno Therapeutics position peaked at $2.97M in Q2 2025.
- 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.
Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.